ArticleVaccines2023

Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates.

Mayanka Awasthi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.